L-DOPA treatment for Parkinson’s disease frequently leads to dyskinesias, the pathophysiology of which is poorly understood. We used MALDI-MSI to map the distribution of l-DOPA and monoaminergic pathways in brains of dyskinetic and nondyskinetic primates. We report elevated levels of l-DOPA, and its metabolite 3-O-methyldopa, in all measured brain regions of dyskinetic animals and increases in dopamine and metabolites in all regions analyzed except the striatum. In dyskinesia, dopamine levels correlated well with l-DOPA levels in extrastriatal regions, such as hippocampus, amygdala, bed nucleus of the stria terminalis, and cortical areas, but not in the striatum. Our results demonstrate that l-DOPA–induced dyskinesia is linked to a dysregulation of l-DOPA metabolism throughout the brain. The inability of extrastriatal brain areas to regulate the formation of dopamine during l-DOPA treatment introduces the potential of dopamine or even l-DOPA itself to modulate neuronal signaling widely across the brain, resulting in unwanted side effects.
Mass spectrometry imaging (MSI) is a powerful tool for spatial metabolomics and biomarker discovery, but molecular identification remains challenging, particularly for low‐abundance analytes with poor signal‐to‐noise ratios. Herein, a novel approach that utilizes a deuterated analog of the reactive matrix FMP‐10 to enhance molecular identification is introduced. This isotopically labeled matrix enables precise determination of derivatization patterns, allowing the number and sequence of reactive functional groups in small molecules to be deduced. By observing specific mass shifts, the method provides additional structural information beyond high‐resolution MS and MS/MS, addressing key limitations in MSI‐based biomarker discovery. This innovative labeling strategy improves identification confidence for neurotransmitters and metabolites, making it a powerful addition to the MSI toolbox for complex tissue analysis. The findings represent a significant advance for spatial metabolomics, with particular advantages for neurochemical mapping in the study of neurodegenerative diseases.